Travaux scientifiques

Doç. Dr. Umut Dişel

78 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies

    Journal of Immunotherapy and Precision Oncology, 2026

    DOI 10.36401/jipo-25-34 PMID 41868199 Texte intégral en libre accèsSource : OpenAlex

  2. CYLD Mutations, PD-L1 and HPV; A Pan-Cancer Landscape Analysis

    Research Square, 2026

    DOI 10.21203/rs.3.rs-10854026/v1 PMID 42818505 Source : OpenAlex

  3. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  4. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Texte intégral en libre accèsSource : OpenAlex

  5. Uniform Reporting of Next Generation Sequencing: Indian Society of Medical and Pediatric Oncology

    Indian Journal of Medical and Paediatric Oncology, 2025

    DOI 10.1055/s-0045-1806726 Source : OpenAlex

  6. Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20659 Source : OpenAlex

  7. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  8. The value of virtual molecular tumor boards for informed clinical decision-making

    The Oncologist, 2024

    DOI 10.1093/oncolo/oyae077 PMID 38761380 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  9. Demographic and survival data of patients with primary diffuse large B-cell lymphoma of the head and neck: A single center experience.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e19069 Source : OpenAlex

  10. Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad230 PMID 37589222 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  11. Clinical assessment of HRD scoring in relation to PARPi response in terms of statistical guidance on reporting results for CDx tests evaluation.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e17597 Source : OpenAlex

  12. Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.e21202 Source : OpenAlex

  13. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

    Cancer Medicine, 2023

    DOI 10.1002/cam4.6869 PMID 38140782 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.21.02453 PMID 35349370 23 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  15. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

    Medicine, 2022

    DOI 10.1097/md.0000000000032368 PMID 36550824 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  16. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-89310 Texte intégral en libre accèsSource : OpenAlex

  17. 124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.03.138 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  18. 1421P EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1530 Source : OpenAlex

  19. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e13646 1 citation (OpenAlex) Source : OpenAlex

  20. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

    The Oncologist, 2019

    DOI 10.1634/theoncologist.2018-0528 PMID 31604903 27 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  21. Frequency of genomic biomarkers of response to immunotherapy in sarcoma.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.11579 Source : OpenAlex

  22. Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.11576 Source : OpenAlex

  23. Co-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases

    Annals of Oncology, 2017

    DOI 10.1093/annonc/mdx390.005 Source : OpenAlex

  24. Febrile neutropenia due to H1N1 infection: Rare entity

    Journal of Oncological Sciences, 2016

    DOI 10.1016/j.jons.2015.11.001 Texte intégral en libre accèsSource : OpenAlex

  25. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

    Oncoscience, 2015

    DOI 10.18632/oncoscience.175 PMID 26244165 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Prolonged use of bevacizumab may cause extensive coronary artery thrombosis.

    PubMed, 2014

    PMID 24965427 Source : OpenAlex

  27. J Clin Hypertens (Greenwich) 2011 Diel U

    2014

    Source : OpenAlex

  28. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.

    PubMed, 2013

    PMID 23613414 7 citations (Europe PMC) Source : OpenAlex

  29. Secondary malignancy after imatinib therapy: eight cases and review of the literature

    Leukemia & lymphoma/Leukemia and lymphoma, 2012

    DOI 10.3109/10428194.2012.666545 PMID 22329351 16 citations (Europe PMC) Source : OpenAlex

  30. Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study

    Medical Oncology, 2012

    DOI 10.1007/s12032-012-0254-4 PMID 22729367 8 citations (Europe PMC) Source : OpenAlex

  31. Which patients with advanced cancer and biliary obstruction benefit from biliary stenting most? An analysis of prognostic factors

    Supportive Care in Cancer, 2012

    DOI 10.1007/s00520-012-1636-z PMID 23132146 4 citations (Europe PMC) Source : OpenAlex

  32. HER-2 Pozitif Meme Kanserinde Anti-HER-2 Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2012

    Source : OpenAlex

  33. A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit

    Oral Oncology, 2011

    DOI 10.1016/j.oraloncology.2011.07.030 PMID 21865077 34 citations (Europe PMC) Source : OpenAlex

  34. Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience.

    PubMed, 2011

    PMID 21875263 15 citations (Europe PMC) Source : OpenAlex

  35. Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience

    European Journal of Radiology, 2011

    DOI 10.1016/j.ejrad.2011.04.056 PMID 21596502 4 citations (Europe PMC) Source : OpenAlex

  36. Hypertension Associated With Angiogoenesis Inhibitors: What Do Oncologists Really Do in Daily Routine? A Small Survey

    Journal of Clinical Hypertension, 2011

    DOI 10.1111/j.1751-7176.2011.00526.x PMID 22051434 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  37. Patients with advanced cholangiocarcinoma benefit from chemotherapy if they are fit to receive it: single center experience.

    PubMed, 2011

    PMID 22006752 1 citation (Europe PMC) Source : OpenAlex

  38. Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e16001 15 citations (OpenAlex) Source : OpenAlex

  39. The evaluation of demographic, clinicopathologic characteristics, and treatment modalities of malignant pleural mesothelioma in southwest of Turkey: A single-center experience.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e18037 Source : OpenAlex

  40. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation

    Lung Cancer, 2010

    DOI 10.1016/j.lungcan.2010.09.011 PMID 20970876 28 citations (Europe PMC) Source : OpenAlex

  41. Unilateral hand–foot syndrome: an extraordinary side effect of capecitabine

    Cutaneous and Ocular Toxicology, 2010

    DOI 10.3109/15569521003699585 PMID 20298142 14 citations (Europe PMC) Source : OpenAlex

  42. Severe Pulmonary Toxicity Associated with Fludarabine and Possible Contribution of Rituximab

    Chemotherapy, 2010

    DOI 10.1159/000305255 PMID 20357439 5 citations (Europe PMC) Source : OpenAlex

  43. How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About “M-Neoadjuvant” and “M-Adjuvant”?

    Annals of Surgical Oncology, 2010

    DOI 10.1245/s10434-010-1011-6 PMID 20217255 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  44. Letter to the editor

    Supportive Care in Cancer, 2010

    DOI 10.1007/s00520-010-0842-9 PMID 20376503 Source : OpenAlex

  45. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up

    Nuclear Medicine Communications, 2009

    DOI 10.1097/mnm.0b013e328332b340 PMID 19952921 12 citations (Europe PMC) Source : OpenAlex

  46. Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate

    Leukemia & lymphoma/Leukemia and lymphoma, 2009

    DOI 10.1080/10428190802603169 PMID 19197737 7 citations (Europe PMC) Source : OpenAlex

  47. Immediate or Delayed Docetaxel: Does Progression-Free Survival Really Reflect Two Strategies?

    Journal of Clinical Oncology, 2009

    DOI 10.1200/jco.2009.22.3305 PMID 19398567 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  48. 5106 Predictive risk factors for brain metastasis in breast cancer

    European Journal of Cancer Supplements, 2009

    DOI 10.1016/s1359-6349(09)70998-x Source : OpenAlex

  49. Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature

    Leukemia Research, 2007

    DOI 10.1016/j.leukres.2007.01.005 PMID 17328950 17 citations (Europe PMC) Source : OpenAlex

  50. Gravin gene expression in acute leukaemias: Clinical importance and review of the literature

    Leukemia & lymphoma/Leukemia and lymphoma, 2007

    DOI 10.1080/10428190701377055 PMID 17577780 10 citations (Europe PMC) Source : OpenAlex